Status:
COMPLETED
Study for Treatment of Cancer in Children With Ataxia-telangiectasia
Lead Sponsor:
St. Jude Children's Research Hospital
Collaborating Sponsors:
Children's Hospital of Philadelphia
National Cancer Institute (NCI)
Conditions:
Ataxia-Telangiectasia
Eligibility:
All Genders
Up to 10 years
Phase:
NA
Brief Summary
This is a pilot/feasibility study designed to investigate the feasibility of treating children with Ataxia-Telangiectasia (A-T) and cancer with regimens nearly as intense as non-A-T patients with canc...
Detailed Description
Approximately 10-30% of A-T patients will develop a malignancy during their lifetime. The vast majority of these cancers are of lymphoid origin. There is no consensus regarding the optimal strategy fo...
Eligibility Criteria
Inclusion
- Patient must have a diagnosis of Ataxia-Telangiectasia (A-T).
- Patient must have a diagnosis of either acute lymphoblastic leukemia (ALL) or lymphoma (non-Hodgkin lymphoma or Hodgkin's disease).
- Patients with other malignancies (solid tumors, rare malignancies, or relapsed hematopoietic malignancies) will be eligible for the biologic studies of this protocol; they will receive best clinical management chemotherapy.
- Patients do not have to be previously untreated. If prior chemotherapy has already started (up through induction), therapy will be continued according to protocol at a clinically appropriate time point.
Exclusion
- Patients who do not have a diagnosis of Ataxia Telangiectasia (A-T).
Key Trial Info
Start Date :
September 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2013
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT00187057
Start Date
September 1 2002
End Date
June 1 2013
Last Update
August 27 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St. Jude Children's Research Hospital
Memphis, Tennessee, United States, 38105